The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Distribution of homologous recombination deficiency (HRD) and BRCA mutations (m) detected by HRD-One test among Brazilian patients (pts) with newly diagnosed advanced epithelial ovarian, fallopian tube, or peritoneal cancer.
 
Mariana Scaranti
Honoraria - AstraZeneca/Merck; GlaxoSmithKline; MSD; Zodiac Pharma
Consulting or Advisory Role - AstraZeneca/Merck; GlaxoSmithKline; MSD; Zodiac Pharma
Speakers' Bureau - AstraZeneca/Merck; GlaxoSmithKline; MSD; Zodiac Pharma
 
Guilherme Lopes Yamamoto
Research Funding - AstraZeneca/Merck (Inst)
 
Rodrigo Guarischi Sousa
No Relationships to Disclose
 
Ana Carolina J Paniza
No Relationships to Disclose
 
Fernanda Milanezi
No Relationships to Disclose
 
Cristovam Scapulatempo-Neto
Speakers' Bureau - AstraZeneca/Merck; Merck Sharp & Dohme
Research Funding - AstraZeneca/Merck (Inst)
Patents, Royalties, Other Intellectual Property - Patent BR 10 2014 003033 6 . A molecular test miRNA based for determination of primary sites of carcinoma of inknown primary (Inst)